Blockade of interferon signaling decreases gut barrier integrity and promotes severe West Nile virus disease

Shih-Ching Lin
Fang R Zhao
Hana Janova
Adrian Gervais
Summer Rucknagel

See next page for additional authors

Follow this and additional works at: https://digitalcommons.wustl.edu/oa_4

Part of the Medicine and Health Sciences Commons

Please let us know how this document benefits you.
Authors
Shih-Ching Lin, Fang R Zhao, Hana Janova, Adrian Gervais, Summer Rucknagel, Kristy O Murray, Jean-Laurent Casanova, and Michael S Diamond
Blockade of interferon signaling decreases gut barrier integrity and promotes severe West Nile virus disease

Shih-Ching Lin1,13, Fang R. Zhao1,13, Hana Janova1, Adrian Gervais2,3, Summer Rucknagel4, Kristy O. Murray5, Jean-Laurent Casanova2,3,6,7,8 &, Michael S. Diamond1,9,10,11,12

Received: 12 August 2023
Accepted: 29 August 2023
Published online: 25 September 2023

The determinants of severe disease caused by West Nile virus (WNV) and why only ~1% of individuals progress to encephalitis remain poorly understood. Here, we use human and mouse enteroids, and a mouse model of pathogenesis, to explore the capacity of WNV to directly infect gastrointestinal (GI) tract cells and contribute to disease severity. At baseline, WNV poorly infects human and mouse enteroid cultures and enterocytes in mice. However, when STAT1 or type I interferon (IFN) responses are absent, GI tract cells become infected, and this is associated with augmented GI tract and blood-brain barrier (BBB) permeability, accumulation of gut-derived molecules in the brain, and more severe WNV disease. The increased gut permeability requires TNF-\(\alpha\) signaling, and is absent in WNV-infected IFN-deficient germ-free mice. To link these findings to human disease, we measured auto-antibodies against type I IFNs in serum from WNV-infected human cohorts. A greater frequency of auto- and neutralizing antibodies against IFN-\(\alpha2\) or IFN-\(\omega\) is present in patients with severe WNV infection, whereas virtually no asymptomatic WNV-infected subjects have such antibodies (odds ratio 24 [95% confidence interval: 3.0 – 192.5; \(P=0.003\)). Overall, our experiments establish that blockade of type I IFN signaling extends WNV tropism to enterocytes, which correlates with increased gut and BBB permeability, and more severe disease.

West Nile virus (WNV) is a positive-stranded RNA flavivirus in the Flaviviridae family that is transmitted by mosquitoes and is related to other clinically relevant viruses, including dengue (DENV), Zika (ZIKV), Japanese encephalitis (JEV), yellow fever (YFV), and tick-borne encephalitis (TBEV) viruses. WNV infection of neurons in the central nervous system (CNS) can cause injury in the cerebral cortex, brain stem, and spinal cord1,2, and lead to severe disease including meningitis, encephalitis, and death in humans, horses, and other vertebrate animals1. The majority (approximately 80%) of WNV infections in humans are asymptomatic. Of the 20% of infections that cause symptoms, most individuals experience self-limited febrile illnesses with only 1% of infected individuals developing severe neuroinvasive disease3,4. While older age is known to be the biggest epidemiologic risk factor5,6, the immunologic and genetic determinants of severe WNV disease in this population are less well understood.

In several animal species, WNV also infects the gastrointestinal (GI) tract, resulting in immune cell infiltration, villus blunting, enterocyte necrosis, and intestinal dysmotility3,4,6. WNV infection of the GI tract occurs through hematogenous spread7, as the virus is inactivated by the acidic milieu of the stomach8. Reports of WNV infection in humans describe symptoms of GI tract infection or inflammation (e.g., vomiting, diarrhea, and/or abdominal pain)9,10. Although intestinal tissues from rodents, birds, and human patients show evidence of WNV RNA and antigen9,11,12, the tropism of WNV in the GI tract, apart
from infection of neurons and its effects on pathogenesis, remains poorly characterized.

The type I interferon (IFN) signaling pathway is a first line of defense against many viral infections, including WNV. IFNs induce expression of hundreds of IFN-stimulated genes (ISGs), a subset of which inhibit different steps in the infection cycle of viruses. WNV infection and pathogenesis are restricted by pre-treatment of cells or animals with type I IFNs. Moreover, mice lacking type I IFNs or their shared IFNAR1/IFNAR2 receptor are vulnerable to subcutaneous inoculation of WNV and develop encephalitis and lethal infection at high frequency.

In humans, type I IFN antiviral responses can be compromised by rare genetic deficiencies in signaling and adaptor molecules (e.g., TLR3, TLR7, IRF7, IFNAR1, IFNAR2) or through the production of auto-antibodies (Abs) against type I IFNs. In several cohorts of patients hospitalized with COVID-19 or influenza, the relative risk of severe disease and death was much greater in individuals with neutralizing Abs against type I IFN. Related to this, auto-Abs to type I IFNs were associated with adverse reactions and outcomes after immunization with the live-attenuated vaccine against yellow fever, a flavivirus related to WNV.

Here, we explored the dynamics of WNV infection of enterocytes and the GI tract by evaluating the effect of host IFN restriction on viral replication using human and mouse intestinal enteroids, and an established subcutaneous infection model in C57BL/6j mice. Human and mouse intestinal organoid cultures have been used as models to study virus-host interaction in the GI tract. Intestinal enteroids can be differentiated to multiple cell types including enterocytes, enteroendocrine cells, goblet cells, and Paneth cells. When STAT1 signaling responses were absent, WNV more efficiently infected enteroids in culture. In vivo, greater enterocyte infection by WNV was observed after subcutaneous virus inoculation in animals with deficiencies in STAT1 or type I IFN signaling function. This pattern of infection was associated with enhanced disease and increased permeability of small molecules across GI tract and blood-brain barriers (BBB).

To begin to define the relevance of these findings, we tested convalescent sera for anti-type I IFN auto-Abs in a human WNV infection cohort, which includes asymptomatic subjects or those hospitalized with meningitis/encephalitis and severe disease. Notably, a substantive fraction of severe WNV cases had measurable auto-Abs and neutralizing Abs against IFN-α2 or IFN-ω, two circulating type I IFN subtypes, whereas almost none of the asymptomatic subjects had these Abs. Treatment of human intestinal enteroids with serum from subjects with anti-IFN auto-Abs resulted in enhanced viral infection. Collectively, our experiments establish that defects in type I IFN signaling can enable WNV infection of epithelial cells in the GI tract, and this correlates with more severe disease in both mice and humans.

**Results**

WNV replicates in mouse and human intestinal organoids and is restricted by type I IFN responses

To begin to determine the permissivity of WNV infection for non-neuronal cells in the GI tract, we assessed whether WNV New York-1999 strain (herein, WNV) could productively infect mouse and human enteroids derived from healthy donors. Since STAT1 is a key transcription factor downstream of IFN signaling that induces antiviral ISG expression and can be a determinant of cell and species tropism for viruses, we first compared WNV infection in small intestinal (duodenum) cultures from wild-type and Stat1−/− mice. All wild-type enteroid cultures showed limited viral replication at a multiplicity of infection (MOI) of 0.5, with less than 100-fold increases in viral RNA at 96 hours post-infection (hpi). In contrast, Stat1−/− mouse enteroids were more permissive to WNV infection (Fig. 1a). For human enteroids, we inoculated wild-type (J2) and congenic STAT1−/− (generated by CRISPR/Cas9 gene editing) jejunal enteroids with WNV. Again, limited infection was observed in wild-type enteroids, but substantially greater viral RNA levels (~22.4-fold increase at 96 hpi) were measured in the supernatants of STAT1−/− enteroids (Fig. 1b).

To identify the targets of WNV infection in the culture, we stained enteroid monolayers with Abs against WNV and different cell markers, and found that WNV infects villin- and EpCAM-expressing epithelial cells in STAT1-deficient monolayers, compared to limited infection in wild-type enteroids (Fig. 1c). Thus, STAT1-dependent signaling restricted WNV infection in vitro in both mouse and human intestinal epithelial-lineage cells.

WNV infection in the GI tract is restricted by IFN responses

To investigate the role of STAT1 and IFN signaling in modulating WNV tropism in the GI tract, we inoculated 9-10-week-old male wild-type, Ifnar1−/−, Ifngr−/− (loss of IFN-γ signaling), Ifn1−/− (loss of IFNα signaling), and Stat1−/− mice via a subcutaneous route with 10⁴ focus-forming units (FFU) of WNV. We also examined the effects of an acquired deficiency of type I IFN signaling by treating wild-type mice with a blocking anti-IFNAR1 Ab prior to WNV inoculation. At 5 days post-infection (dpi), wild-type mice showed sparse enteric neuronal infection in the myenteric plexus without apparent epithelial cell infection in the GI tract (Fig. 2a). Similar results were observed in Ifngr−/− and Ifn1−/− mice, suggesting that type II and III IFN pathways do not have dominant roles in restricting WNV infection of GI tract epithelial cells (Supplementary Fig 1a). In comparison, both Ifnar1−/− and Stat1−/− mice showed extensive WNV antigen staining in the myenteric plexus, the lamina propria, and enterocyte layers, with greater infection in the duodenum than other intestinal segments (Fig. 2a and Supplementary Fig 1b); as the enterocyte infection phenotype appeared more prominent in Stat1−/− than Ifnar1−/− mice, signaling from IFN-α1, IFN-γ, or other cytokines upstream of STAT1 signaling might still contribute to control of WNV infection in the GI tract, particularly in the absence of type I IFN signaling. Consistent with these results, wild-type mice treated with a blocking anti-IFNAR1 antibody also showed extensive WNV infection throughout the GI tract at 5 dpi, with antigen staining that was similar in distribution to that seen in Ifnar1−/− mice (Fig. 2a,b).

WNV infection alters barrier permeability in type I IFN signaling-deficient mice

Given that WNV can infect the intestinal epithelium (enterocytes) in mice with deficient type I IFN signaling (Fig. 2c), we investigated the functional effects on barrier integrity. To evaluate GI tract permeability at 5 dpi, we administered fluorescently-conjugated dextrans of different molecular weights (Cascade Blue [10 kDa], Tetramethylrhodamine [70 kDa], and FITC [250 kDa]) to WNV-infected mice by oral gavage and measured translocation into circulation. Compared to uninfected or isotype control Ab-treated WNV-infected animals, WNV-infected mice that received anti-IFNAR1 antibody accumulated higher levels of all three dextrans in their sera (Fig. 2d), indicating that deficient type I IFN signaling and associated WNV infection of the GI tract correlates with increased intestinal barrier permeability. However, culture of blood did not yield any bacterial growth (Supplementary Table 1), suggesting that gut barrier integrity was compromised principally for smaller molecules such as constituents of bacteria and dietary products.

We next evaluated whether the enhanced GI tract permeability led to accumulation of gut constituents in the brains of anti-IFNAR1-treated mice. At 5 dpi, WNV-infected mice that were treated with anti-IFNAR1 antibody showed evidence of fluorescently-labelled dextran in the brain (Fig. 3a-b) that was administered by oral gavage. Uninfected mice or WNV-infected mice with intact type I IFN responses did not show this accumulation. These findings correlated with WNV infection, with anti-IFNAR1 antibody-treated mice showing higher levels of WNV antigen in the GI tract (Fig. 2a-c) and brain (Fig. 3c), and viral RNA in the serum, spinal cord, and brain compared to animals treated with the...
**Fig. 1 | WNV infection of mouse and human intestinal enteroids is restricted by STAT1-dependent signaling.** WT and STAT1-deficient mouse and human intestinal enteroids were inoculated with WNV (MOI of 0.5 for mouse and 0.1 for human enteroids) and cultured at 37°C for the indicated time points. a, b Viral RNA extracted from supernatants and cell monolayers of mouse (a) or human (b) organoids was quantitated by RT-qPCR. Bars illustrate geometric means, and dotted lines show limits of detection (LOD). Each data point represents an individual well (n = 9 per group from 3 independent experiments). Statistical analysis: two-tailed Mann-Whitney test: ****P < 0.0001 (a); ***P = 0.0002, ****P < 0.0001 (b). c Human organoids cultured under air-liquid interface conditions were inoculated with WNV (MOI of 10) for 72 h, then fixed and stained with antibodies against WNV antigen (red), villin (green), and EpCAM (white), and counterstained for the nuclei (Hoechst 33258, blue). Scale bar, 100 μm. Data are representative of 3 experiments.
Fig. 2 | WNV infection in the GI tract is restricted by type I IFN responses. \textit{Stat1}\textsuperscript{−/−} and \textit{Ifnart1}\textsuperscript{−/−} mice, as well as WT mice treated with either isotype control or blocking IFNAR1 antibodies, were inoculated subcutaneously in the footpad with 10\textsuperscript{2} FFU of WNV. a Immunofluorescent confocal microscopy imaging of duodenal and jejunal cryosections of the GI tract at 4-5 dpi show WNV antigen (red), Paneth and goblet cells (UEA-1, green), EpCAM (white), and nuclei (Hoechst 33258, blue). Scale bar, 100 \( \mu \)m. Data are representative of 4 experiments; from left to right, \( n = 8 \), 13, 15, 8, 12, 8, 11, 11, and 15 mice per group. b Quantitation of WNV antigen positive cells in different regions along the GI tract was determined as a percentage of total Hoechst 33258-positive cells per field (b) or as a percentage of total EpCAM-positive epithelial cells per field (c). Lines indicate mean values. Data are from 4 experiments; from left to right, \( n = 13, 15, 8, 12, 8, 11, 11, \) and 15 per group. d Serum concentrations of 10, 70, and 250 kDa dextrans at 3 h after oral gavage in uninfected or WNV-infected (5 dpi) mice treated with anti-IFNAR1 or isotype control Ab. Data are from 3 experiments with lines indicating mean values; from left to right, \( n = 9, 6, 16, 16, 9, 6, 16, 9, 6, 8, \) and 7 mice per group. Statistical analysis, from left to right: (b, c) two-tailed Mann-Whitney test: \( ***P < 0.0001, \ ****P = 0.0013, \ **P = 0.0094, \ *P = 0.0004 \); \( ****P < 0.0001 \); and (d) two-tailed Mann Whitney test with Bonferroni correction: ns, not significant, \( ***P = 0.0006, \ **P = 0.0003, \ *P = 0.0036. \)
We separately assessed the effect of anti-IFNAR1 treatment on BBB permeability after WNV infection by intravenously administering fluorescently conjugated dextrans to bypass effects in the GI tract. At 5 dpi, anti-IFNAR1-treated mice showed evidence of increased BBB permeability and accumulation of dextrans in the perivascular space and parenchyma of several regions of the brain including the olfactory bulb, brainstem, and cerebellum (Supplementary Fig 3a-f). This result is consistent with prior data showing that type I IFNs stabilize the BBB.

isotype control antibody (Fig. 3d-f). These in vivo studies suggest that the GI tract barrier is impaired after WNV infection when type I IFN responses are compromised, and this correlates with enhanced infection in these tissues. However, we did not observe an increase in gut permeability to the 250 kDa FITC-dextran that we measured after anti-IFNAR1 treatment at 3 dpi (Supplementary Fig 2b), even though viral RNA was present in the serum, liver, and brain (Supplementary Fig 2c-e).

We separately assessed the effect of anti-IFNAR1 treatment on BBB permeability after WNV infection by intravenously administering fluorescently conjugated dextrans to bypass effects in the GI tract. At 5 dpi, anti-IFNAR1-treated mice showed evidence of increased BBB permeability and accumulation of dextrans in the perivascular space and parenchyma of several regions of the brain including the olfactory bulb, brainstem, and cerebellum (Supplementary Fig 3a-f). This result is consistent with prior data showing that type I IFNs stabilize the BBB.
tight junctions after injection of pathogen-associated molecular patterns or infection by WNV.48

GI tract permeability and disease severity is diminished in germ-free mice

We next evaluated whether GI tract barrier permeability changes associated with type I IFN blockade and WNV infection may be linked to the presence of a gut microbiota, since commensal bacterial components can modulate cellular junctions and barrier integrity49,50. We treated 9-10-week-old germ-free (GF) C57BL/6J mice with isotype control or anti-IFNAR1 antibody, followed by subcutaneous inoculation with 10^2 FFU of sterile-filtered WNV. At 3 or 5 dpi, we orally gavaged GF animals with 250 kDa FITC-conjugated dextran. At 3 dpi, no differences in GI tract permeability were observed with anti-IFNAR1 treatment of specific pathogen-free (SPF, conventional microbiota) and GF mice (Supplementary Fig 2a), although moderately lower levels of viral RNA were observed in the liver (4-fold, p < 0.01) and brain (4-fold, p < 0.05) but not serum of GF mice (Supplementary Fig 2c-e). At...
5 dpi, and in contrast to that seen in anti-IFNAR1 antibody-treated SPF mice, GF mice did not show enhanced GI tract permeability when type I IFN signaling was blocked (Fig. 3g) even though substantial WNV infection was present in enterocytes from all segments of the GI tract (Supplementary Fig 4a-c). Similarly, GF mice treated with anti-IFNAR1 antibody showed reduced BBB permeability compared to similarly treated SPF mice at 5 dpi (Supplementary Fig 3). Additionally, although anti-IFNAR1 antibody-treated GF mice exhibited higher levels of orally gavaged FITC-dextran accumulation in the brain compared to isotype control antibody-treated GF mice, the level was lower than in conventionally-housed SPF animals (Fig. 3a-b). Nonetheless, similar levels of WNV infection were detected in the serum, brain, and spinal cord of anti-IFNAR1-treated GF animals by antigen staining (Fig. 3a and c) or RT-qPCR (Fig. 3d-f) at 5 dpi. These results suggest that while certain components of the host microbiota may affect GI tract and BBB permeability, and accumulation in the brain of circulating molecules or proteins, WNV may use other mechanisms (e.g., Trojan horse effect of WNV-infected blood cells, direct infection of endothelial cells, or transcytosis of gut constituents into circulation after type I IFN signaling blockade in SPF mice can promote tissue inflammation and damage. The necrotic liver injury was not due to bacterial infection, as culture of liver homogenates from WNV-infected anti-IFNAR1-treated SPF mice did not yield bacterial growth (Supplementary Table 1). To determine the clinical consequences of enhanced GI tract infection and permeability, we measured changes in body weight of mice after WNV infection and anti-IFNAR1 treatment. Notably, GF mice treated with anti-IFNAR1 antibodies exhibited less weight loss after WNV infection than similarly-treated SPF mice (Fig. 4f). Moreover, anti-IFNAR1/anti-TNF-α-treated SPF mice also showed less weight loss than SPF mice that received anti-IFNAR1 but not anti-TNF-α antibody (Fig. 4d), indicating the TNF-α signaling is critical for WNV pathogenesis in this setting.

Given the findings with anti-TNF-α antibody, we broadly measured serum cytokine levels in SPF and GF mice in the context of type I IFN signaling blockade at 5 dpi. Anti-IFNAR1-treated WNV-infected SPF mice accumulated substantially higher levels of pro-inflammatory cytokines and chemokines (IFN-γ, TNF-α, IL-6, G-CSF, CXCL10, IL-5, CCL2, CXCL9, IL-12p40, and CCL5) than WNV-infected SPF mice treated with an isotype-control antibody or uninfected mice treated with either anti-IFNAR1 or isotype control antibody (Fig. 4g). Because pro-inflammatory cytokines can impact microglia or macrophage activation and neuronal function in the brain43,44, we assessed the effects of anti-IFNAR1 treatment in SPF and GF mice. Compared with the brains of infected SPF mice or WNV-infected anti-IFNAR1-treated GF mice, anti-IFNAR1-treated SPF mice at 5 dpi showed more prominent changes in morphology and greater numbers of Iba1 cells (Supplementary Fig 8a-c), that are characteristic of activated microglia and/or increased infiltration of monocyte-derived macrophages45.

**Auto-Abs against type I IFN in human patients with severe WNV infection**

Recent studies have suggested that pathological responses to live-attenuated yellow fever vaccine33, severe influenza35 and SARS-CoV-2 infections34,35,36, occur more frequently in older humans with auto-Abs to type I IFNs34,35,36. Given that severe WNV infection in the CNS occurs in the elderly37, we hypothesized that part of the enhanced risk might be due to an acquired deficiency of type I IFN signaling, which could impact infection and barrier permeability. To test this idea, we acquired convalescent serum from a cohort of asymptomatic WNV-infected subjects who were identified as viremic through blood bank donations (n = 19) and a separate cohort of hospitalized subjects with severe WNV neuroinvasive disease, all diagnosed with encephalitis
To link these results with our GI tract infection data, we evaluated whether sera from WNV patients with auto-IFN Abs could blunt antiviral type I IFN responses in human enteroids. In a first set of experiments, we tested for effects of sera on infection by an IFN-sensitive virus (lymphocytic choriomeningitis virus [LCMV]); we did not use WNV for these studies because the sera from convalescent WNV-infected subjects had neutralizing anti-WNV antibodies. LCMV infection of human enteroids was restricted by pretreatment of cultures with IFN-α2 (Fig. 5g). When IFN-α2 was pre-mixed with human sera from selected WNV subjects who experienced neuroinvasive disease and contained auto-Abs to type I IFN, LCMV replication was restored (Fig. 5h). As the restoration was not observed in IFNAR1−human organoids with the same treatment (Fig. 5i), the increased of LCMV replication was due to the neutralization of IFN-α2 by human sera. Next, to test the effect of sera containing type I IFN auto-Abs on WNV infection of human enterocytes, we utilized sera from patients with autoimmune polyglucanoid syndrome type 1 (APS-1) that contain auto-Abs against type I IFNs but had never been infected with WNV (verified by prescreening ELISA). As expected, WNV infection was inhibited by IFN-α2 pretreatment (Fig. 5j), and the addition of sera from APS-1 patients restored WNV infection in human enteroid cultures (Fig. 5k). Thus, in the subset of WNV encephalitis human patients that develop high levels of auto-Abs to type I IFN, viral infection of enteric cells is likely greater, which could impact disease severity through effects on viral replication and barrier permeability.

### Discussion

In this study, we showed that human and mouse enteroids are largely resistant to WNV infection unless STAT1 signaling is absent due to genetic defects. Analysis of GI tract tissues from mice demonstrated that enterocytes, especially from the duodenum, can be targeted by WNV when blocking anti-IFNAR1 antibodies are administered or in the context of genetic deficiencies in STAT1 and IFNAR1 but not IFNLR1 or IFNGR. The lack of WNV infection of enterocytes in ifi144− mice was unexpected given that IFN-α is an important antiviral restriction factor for other viruses that infect epithelial cells in the GI tract including norovirus and rotavirus. Possibly, a deficiency of IFN-α signaling (or IFN-γ signaling), by itself, is not sufficient to enable WNV to access enterocytes due to a lack of infection of underlying lamina propria cells. Unlike norovirus and rotavirus, which infect enterocytes from the gut lumen after oral ingestion, WNV infects the skin and spreads via the blood to the myenteric plexus and lamina propria of GI tract, and likely infects enterocytes from the basolateral side. Indeed, we did not observe enterocyte infection by WNV after subcutaneous inoculation of inbred-Cre x Stat1−/− mice, which lack STAT1 expression only in GI tract epithelial cells (Supplementary Fig 10a), likely because WNV did not productively infect the underlying stromal and/or immune cells (Supplementary Fig 10b). In contrast, a deficiency of type I IFN signaling in myeloid cells was previously shown to cause dysregulated cytokine responses, complement activation, sepsis, and organ damage, although intestinal infection was not evaluated in that study.

In the setting of type I IFN signaling deficiencies, enhanced WNV infection in the lamina propria and enterocytes was associated with greater GI tract permeability to different sized dextrans, but not to bacteria. These dextrans accumulated at higher levels in peripheral circulation and in the brain. WNV infection in the setting of type I IFN signaling blockade also was associated with changes in BBB permeability, as reported previously. Together, these effects resulted in more severe clinical disease. However, changes in GI tract permeability and accumulation of dextrans in the brain were decreased in WNV-infected, anti-IFNAR1 antibody-treated GF mice and in anti-TNF-α antibody-treated SPF mice, suggesting that elements of the microbiota may be required for inducing pro-inflammatory signals and cytokines, particularly TNF-α, that modulate barrier permeability. These findings are consistent with the concept that changes in the microbiota composition can modulate functions in the brain via actions of

### Table 1 | Demographics and clinical data of WNV-infected subjects

<table>
<thead>
<tr>
<th>Age, years</th>
<th>Asymptomatic WNV N = 19</th>
<th>Neuroinvasive WNV N = 56</th>
</tr>
</thead>
<tbody>
<tr>
<td>Male sex</td>
<td>57 (23)</td>
<td>59.5 (21)</td>
</tr>
<tr>
<td>Ethnicity/Race</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Caucasian</td>
<td>94.7%</td>
<td>76.8%</td>
</tr>
<tr>
<td>African American</td>
<td>5.3%</td>
<td>8.9%</td>
</tr>
<tr>
<td>Hispanic</td>
<td>0%</td>
<td>10.7%</td>
</tr>
<tr>
<td>Asian or Pacific Islander</td>
<td>0%</td>
<td>3.6%</td>
</tr>
<tr>
<td>Neurological symptoms</td>
<td>–</td>
<td></td>
</tr>
</tbody>
</table>

Subjects presenting with multiple clinical symptoms are listed under each manifested symptom. Values expressed as % or median (interquartile range). WNV, West Nile virus.

(n = 56; Houston West Nile Cohort, 2002-2018)44-46,48 (Table 1). There were no significant differences between the demographic characteristics of patients in the asymptomatic and neuroinvasive WNV groups, including age and sex.

We measured anti-IFN-α2 and IFN-ω auto-Abs by ELISA, and used sera from 5 healthy donors who had no known WNV exposures as negative controls to set cutoff values. Anti-IFN-α2 auto-Abs were more prevalent in sera from subjects with WNV meningitis or encephalitis (14 of 56, 25.0%) than asymptomatic individuals (1 of 19, 5.3%, Fig. 5a). Similar results were observed when we measured auto-Abs against IFN-ω (29 of 56, 51.8% with neuroinvasive infection and 0% in asymptomatic) (Fig. 5b). Although we observed a similar trend for anti-IFN-β auto-Abs in severe infection cases, our detection assay was not robust enough to be conclusive (Supplementary Fig 9). Based on these data, our case-control study revealed an odds ratio of 24 (95% confidence interval, 3.0–192.5; P = 0.003) for severe neuroinvasive WNV disease in association with the presence of auto-Abs against IFN-α2 and/or IFN-ω.

We corroborated these results using an established luciferase ISG reporter gene assay23 to evaluate the ability of patient sera to prevent induction of IFN signaling by reporter cells in response to exogenous type I IFN. Notably, 8 of 56 (14.3%) and 11 of 56 (19.6%) serum samples from subjects with severe neuroinvasive disease neutralized responses to recombinant IFN-α2 and IFN-ω, respectively (Fig. 5c-d). Additionally, 5 of the sera contained auto-Abs that neutralized both type I IFNs (Fig. 5e-f). All of the samples with neutralizing activity against IFNs were from subjects who experienced WNV infection and with severe neuroinvasive disease.

---

References omitted for brevity.
pro-inflammatory cytokines\textsuperscript{67-69}, and thus, modify neurological outcomes of virally-infected patients\textsuperscript{69,70}. Because deficiencies in IFN signaling were associated with WNV infection in enteroids and enterocytes in vivo, we hypothesized that severe neuroinvasive WNV disease might be associated with auto-Abs to type I IFNs. Indeed, in a cohort of 75 WNV-infected subjects from Texas, the frequency of auto-Abs to IFN-\(\alpha\)2 and IFN-\(\omega\) was greater in individuals with encephalitis than those with asymptomatic infection. Our results were recently corroborated by a larger cohort study, which analyzed 401 WNV-infected subjects from the European Union and the United States of America, and concluded that auto-Abs neutralizing type I IFNs are associated with approximately one-third of the cases of severe WNV infection requiring hospitalization\textsuperscript{71}. Nonetheless, in humans, the precise cellular mechanism by which auto-Abs to IFN predispose to severe disease remains uncertain and could reflect increased burden of infection, altered cellular tropism of infection in multiple tissues, and/or changes in BBB permeability due to local loss of IFN signaling and antiviral immunity, as well as effects in the GI tract.
and at other sites\(^6\). Indeed, bacterial constituents (e.g., lipids, cell wall components, and nucleic acids) and type I IFN signaling both can directly regulate BBB integrity and function\(^6\).

The role of the gut microbiota in WNV pathogenesis can depend on the immune status of the host. In immunocompetent C57BL/6 mice, antibiotic-induced perturbations in the microbiota can negatively impact CNS T cell responses, which affect viral clearance and survival\(^5\); in this case, an intact and balanced microbiota had a protective role in instructing adaptive T cell responses against WNV infection. However, in the context of an innate immune deficiency (e.g., Ifnar\(^-\) mice, anti-IFNAR blocking antibody treatment of mice, and by inference auto-antibodies to type I IFNs in humans), the microbiota appears to have a detrimental role because it is a source of PAMPs that exacerbate systemic inflammation in the setting of enhanced GI tract infection and loss of barrier integrity. Thus, in immunocompetent and immunodeficient animals, the microbiota can have distinct effects on innate and adaptive immune responses and clinical outcomes during virus infection.

Limitations of the study
We acknowledge several limitations in our experiments: (a) for the organoid cultures, we did not address the effects of the microbiota, bioactive metabolites, or host immune cells, all of which could independently impact WNV infection, cell survival, and cell structural integrity; (b) we did not definitively determine the tropism of WNV in specific enterocyte subpopulations in enteroids or in vivo, which will require further immuno histochemical staining with additional cell-type specific markers or single cell RNA sequencing experiments; (c) while our staining experiments suggest that brain microglia and macrophages are differentially activated in WNV-infected anti-IFNAR1-treated SPF and GF mice, the mechanism was not defined. Experiments with antibodies that block the functions of the pro-inflammatory cytokines that were differentially expressed in serum of WNV-infected anti-IFNAR1-treated SPF and GF mice could address this question; and (d) we have not linked the mechanism of disease severity associated with defects in type I IFN signaling identified in mice with that of human patients having auto-Abs to IFNs and WNV encephalitis.

Nonetheless, our results correlating more severe WNV disease and the presence of neutralizing auto-Abs to type I IFNs extend our understanding of how acquired deficiencies of innate immune response pathways can predispose to severe viral infections and poor outcomes. Auto-Abs to type I IFNs are associated with a greater relative risk of severe COVID-19 and COVID-19-induced death\(^10\), severe COVID-19 vaccine breakthrough infections\(^6\), influenza pneumonia\(^3\), and detrimental outcomes after administration of a live-attenuated yellow fever virus vaccine\(^3\). Such studies suggest possible screening strategies and interventions in identified subjects who might be candidates for IFNβ therapy if administered as an early intervention, as was done successfully with a COVID-19 patient\(^2\). Possibly, administration of metabolites (e.g., short chain fatty acids) that promote barrier function or detoxify inflammatory components from the microbiota could be a complementary approach in selected populations to limit the adverse effects of loss of IFN signaling on the integrity of different barriers including the GI tract and the brain\(^3\).

Methods

Viruses

WNV New York 1999 (clone 382-99 [GenBank #AF196835]) was produced by electroporation of in vitro transcribed RNA into BHK21-15 cells\(^2\) and titered on Vero cells\(^2\). LCMV (C13 strain, gift of T. Egawa, Washington University in St. Louis) was propagated in BHK21 cells and titered on Vero cells.

Human serum samples

Serum samples from asymptomatic WNV subjects identified through blood bank donations and a cohort of subjects with severe WNV neuroinvasive disease (Houston West Nile Cohort, Table 1)\(^46\) were obtained with written informed consent under approved protocols following the guidelines of the Human Investigations Committees of The University of Texas Health Science Center, Baylor College of Medicine, and Yale University School of Medicine, aliquoted, and then stored at -80°C\(^47\). The studies received Institutional Review Board approval from Baylor College of Medicine (H-30533). Virally infected WNV infection was determined at the time of acute illness according to CDC guidelines (http://www.cdc.gov/ncidod/dvbid/westnileclinicians/clinidesc.html) as previously described\(^47\). Asymptomatic, acutely infected subjects were identified via nucleic acid amplification testing by Gulf Coast Regional Blood Center\(^4\), and an absence of illness history was confirmed by study coordinators.

Mice

Mouse experiments were carried out in accordance with the recommendations in the Guide for the Care and Use of Laboratory Animals of the National Institutes of Health. The protocols were approved by the Institutional Animal Care and Use Committee at the Washington University School of Medicine (Assurance #A3381-01). Wild-type C57BL/6 J (Jackson Laboratories, #000664) were obtained commercially. Ifnar\(^-\) \(^{[B6(Cg-hifnar1tm2 Hel)]},\) RRID: IMSR_JAX:023255\(^{[B6.129 S7-Ifnar1tm1Hsd]},\) RRID: IMSR_JAX:0032888\(^{[Ifnar1tm1.2Ees]},\) RRID: IMSR_JAX:0282885\(^{[Ifnar1tm1.2Ees]},\) RRID: IMSR_JAX:003259\(^{[Ifnar1tm1.2Dlv]}\), Stat1tm1Mam, RRID: MMRRC_032054-JAX\(^85\), Stat1tm1Dlv, RRID: IMSR_JAX:0126060\(^85\), Villin-Cre \(^{[B6.129.S(Ifnar1tm1.2Ees)Stat1tm1Mam]},\) RRID: IMSR_JAX:0045385\(^6\) and Stat1\(^\beta\) \(^{[B6;129S-Stat1tm1Dlv]},\) RRID: MMRRC_032054-JAX\(^85\) mice (all congenic on a C57BL/6 J background) were bred under pathogen-free conditions at Washington University. C57BL/6 gnotobiotic mice were bred and housed at the Washington University Gnotobiota Core Facility, and the GF status was confirmed through 16 S qPCR analysis of fecal samples (Charles River).

Enteroid cultures

HIE cultures (J2, J2 STI-IKO and J2 IFNAR1-KO) were previously described\(^86\) and purchased (Digestive Disease Core, Baylor College of Medicine). Mouse enteroids were established from duodenum and colon tissues obtained from wild-type and Stat1\(^\beta\) C57BL/6 J mice (Precision Animal Models and Organoids Core, Washington University). Enteroid cultures were maintained and passaged in Matrigel matrix (Corning, #354230) as multilobular three-dimensional (3D) cultures in 24-well plates supplemented with enteroid growth medium (WRNE, with Wnt, R-spondin and Noggin growth factors in 50% L-WRN cell conditioned medium [CM for human organoids, and 50% L-WRN CM only for mouse enteroids]). To generate confluent monolayers, the 3D enteroids were dissociated with TrypLE\(^\text{TM}\) Express (Thermo, #12604-013), filtered with a 40-μm cell strainer (Corning, #431750 and seeded onto collagen IV-coated 96-well plates as monolayers. For air-liquid interface (ALI) cultures, filtered organoid single cells were seeded as monolayers onto collagen IV-coated inserts of transwells (Corning, #3413), then cultured in WRNE medium supplied in both upper and lower chambers in transwells for two days, and the medium in the upper chambers were removed as the air phase for another two days.

Virus infection of enteroid cultures

Following culture in growth medium for 24 h, monolayers were inoculated with viruses. Monolayers (approximately 2 ×10\(^4\) cells/well) were inoculated with WNV at different multiplicities of infection (MOI) (0.1 for human enteroids and 0.5 for mouse organoids, unless otherwise indicated), for 2 h at 37°C in 5% CO\(_2\). The supernatants were harvested at 2 h after inoculation (input virus), and cells were then washed twice with complete medium without growth factors (CMGF\(_3\)) to remove unbound viruses. Inoculated wells were then cultured in growth medium for specified time points to determine WNV replication kinetics. Each experiment was performed at least three times with three technical replicates in each condition.
Focus-forming assay
Virus stocks were titered on Vero cells by focus-forming assay. Vero cells were plated in 96-well plates and infected with serial dilutions of virus. At 16 h post-infection, cells were fixed, incubated with rat anti-WNV antibody, and stained with donkey anti-rat secondary antibody conjugated with horseradish peroxidase (HRP). Foci of infection were detected by addition of TrueBlue substrate (KPL, #5510-0030) and counted with a CTL Immunospot instrument, and infectious viral titers were calculated as focus-forming units (FFU) per mL.

RNA extraction and RT-qPCR
Total RNA was extracted from cultured supernatants, organoid monolayers, tissue homogenates or sera samples using a MagMAX-96 Viral RNA Isolation Kit (Thermo, #AM1836) with the KingFisher™ Flex Purification System (Thermo). RT-qPCR reactions were performed using the TaqMan™ RNA-to-CT™ 1-Step Kit (Applied Biosystems, #4392938) and the QuantStudio 6 Real-Time PCR System. The WNV primer set includes: Forward primer (5’- TCA GCG ATC TCT CCA CCA AAG-3’), Reverse primer (5’- GGG TCA GCA CTT GTG TCA TTG-3’) and probe (56-FAM/TTG CGG ATC ACC AGT GTA GCC-36-TAMRA). The LCMV primer set includes: Forward primer (5’- TGC CTG ACC AAA TGG TCA TTG-3’) and Taqman probe (56-FAM/TTG CGG ATC ACC AGT TTG-36-TAMRA). A standard curve based on quantified WNV and LCMV samples was used to quantitate viral genome equivalents in experimental samples.

Mouse infection and tissue collection
For WNV infection studies in wild-type C57BL/6 mice, 9-10-week-old male mice were inoculated with 10^5 FFU WNV in 50 μL via footpad injection, following anesthesia with xylazine and ketamine hydrochloride. In some experiments, mice were administered mAbs one day prior to infection: anti-IFNAR1 antibody (Leinco #I-401, clone MAR1-5A3) or mouse lgG1 isotype control antibody (200 μg, Biolegend #506352, clone MP6-XT22) or rat IgG1 isotype control anti-TNF-α antibody (200 μg, Biolegend #506352, clone MP6-XT22) or rat IgG1 isotype control antibody (200 μg, Invitrogen, #14-4301-85). For experiments with Stat1* mice, both sexes of mice were tested. Anti-TNF-α antibody (200 μg, Biolegend #506352, clone MP6-XT22) was administered by intraperitoneal injection one day prior to WNV infection to delay early lethality. SPF mice were weighed daily, whereas GF mice were weighed at 0 or 5 dpi. At the indicated times post-infection, mice were administered terminal anesthesia, followed by blood collection via cardiac puncture and extensive perfusion with PBS. Tissues including the GI tract, liver, spleen, spinal cord, and brain were collected, weighed, homogenized in 500 μL of ice-cold PBS (6000 RPM for 60 sec; Roche MagnaLyser) and then clarified by centrifugation (14,000 x g, 4°C for 10 min) prior to downstream assays.

Histological staining and analysis
Liver specimens were fixed in 4% PFA at 4°C, dehydrated in 70% ethanol, cleared with xylenes, and embedded in paraffin. Micromtector-sectioned samples were stained with hematoxylin and eosin following standard protocols. Analysis of liver tissue was performed in a blinded manner using ImageJ software. The percentage of liver necrosis was determined by quantitating the number of pixels within necrotic lesions divided by the total number of pixels in the liver parenchyma. The severity score of ballooned hepatocytes was determined as follows: score 0 = absent; score 1 = 5%; score 2 = 5–10%; score 3 = 10–20%; score 4 = 20–50%; score 5 >= 50%.

Multiplex analysis of cytokines
This study used Luminex xMAP technology for multiplexed quantification of mouse cytokines, chemokines, and growth factors. The multiplexing analysis was performed using the Luminex™ 200 system by Evy Technologies Corp. Thirty-two markers were concurrently measured in the samples using Evy Technologies’ Mouse Cytokine 32-Plex Discovery Assay® (MilliporeSigma, Burlington, Massachusetts, USA) according to the manufacturer’s protocol. The 32-plex consisted of Etanixin, G-CSF, GM-CSF, IFN-γ, IL-1α, IL-1β, IL-2, IL-3, IL-4, IL-5, IL-6, IL-7, IL-9, IL-10, IL-12(p40), IL-12(p70), IL-13, IL-15, IL-17, IP-10, KC, LIF, LIX, MCP-1, M-CSF, MIG, MIP-1α, MIP-1β, MCP-2, RANTES, TNFα, and VEGF. Assay sensitivities of these markers ranged from 0.3 to 30.6 pg/mL for the 32-plex. Individual analyte sensitivity values are available in the MilliporeSigma MILLIPLEX® MAP protocol.

Immunofluorescence staining of GI tracts and organoid monolayers
Sections of GI tract tissue were opened along the mesenteric border, pinned to Sylgard silicon plates, and fixed in 4% paraformaldehyde (PFA, Electron Microscopy Sciences, #15713-S) overnight at 4°C. For staining of WNV antigen, PFA-fixed GI sections were cryopreserved in 30% glucose overnight, embedded in Tissue-Tek O.C.T. Compound (Sakura Finetek USA, #4583), frozen, and then sectioned to 10-μm depth by Cryostat (Leica, #CM1850). Slides were blocked for 1 h at room temperature in Tris-buffered saline (TBS) solution containing 1% bovine serum albumin (BSA), 5% normal donkey serum (Sigma, #D9003), and 0.1% Triton X-100 (Sigma, #T8787). Sections were incubated overnight at 4°C with rat anti-WNV hyperimmune serum (1:7500) and rabbit anti-EpCAM polyclonal serum (1:2000, Abcam #ab71961) or rabbit anti-STAT1 monoclonal antibody (1:1000, Cell Signaling #14994) diluted in IX TBS containing 1% BSA, normal donkey serum, and 0.1% Triton X-100. After three rinses with PBS, the sections were incubated with secondary antibodies: for the dark in the dark for 2 h at room temperature including AF594-conjugated donkey anti-rat antibody (1:1000, Thermofisher #A-21209), AF647-conjugated donkey anti-rabbit antibody (1:1000, Thermofisher #A-31573), and Fluorescein-conjugated Ulex Europaeus Agglutinin I (UEA-1, 1:2000, Thermofisher #L32476) diluted in TBS containing 1% BSA, 3% normal donkey serum, and 0.1% Triton X-100. Following three rinses with PBS and counter-staining with Hoechst 33258 dye (1:20,000 in IX PBS, Thermofisher #H3569) and two additional rinses, tissue sections were mounted in ProLong Glass Antifade Mountant (Invitrogen #P36980) and stored in the dark at 4°C until imaging. For staining of organoid AI monolayers in transwells, the membrane was rinsed with PBS and fixed by 100% methanol at -20°C for 20 min, then blocked with blocking buffer (1X PBS with 2% normal donkey serum, 1% BSA, 0.1% cold fish gelatin, 0.1% Triton X-100, 0.05% Tween 20 and 0.05% NaN3). The membrane was carefully cut out with a blade and transferred into a new well in a 24-well dish, followed by staining with primary antibodies including mouse anti-ZO-1 monoclonal antibody (1:1000, Thermofisher #33-9100) in IX PBS with 1% BSA, 0.1% cold fish gelatin and 0.05% NaN3, and secondary antibody including AF488-conjugated donkey anti-mouse antibody (1:1000, Thermofisher #A-21202) in IX PBS. After staining the membrane was mounted in ProLong Glass Antifade Mountant and stored in the dark at 4°C until imaging as well. All images were acquired using a Zeiss LSM 880 Confocal Laser Scanning Microscope 20x (NA 0.8) objective. The WNV antigen signals in all images was quantified using Fiji ImageJ software. Each data point was derived from measurements of 3 to 5 independent fields per mouse per GI tract segment.

GI tract permeability assay
Intestinal permeability was measured by detecting translocation of dextran from the lumen of the GI tract into the blood. Briefly, at 3 or 5 dpi, mice were gavaged orally with 100 μL of 60 mg/mL of dextrans of different molecular weights conjugated to different fluorescent dyes: Cascade Blue, (10 kDa, Thermo, #D1976), Tetramethylrhodamine (70 kDa, Thermo, #D1818) and FITC (250 kDa, Sigma-Aldrich, #FD2505). At 3 h after dextran administration, mice were administered terminal anesthesia with ketamine/xylazine, and...
blood was collected by cardiac puncture into serum separator tubes (BD Microtainer, #365967) and centrifuged (1500x g, 10 min at 4°C). Fluorescence (360, 490 and 550 nm wavelength absorbance endpoints) was measured with a BioTek Synergy H1 plate reader, and dextran concentrations in the sera were calculated based on standard curves. To evaluate for accumulation of translocated dextrans into the brain using confocal microscopy imaging, brain tissues were fixed in 4% PFA overnight at 4°C, embedded in Tissue-Tek O.C.T. Compound (Sakura Finetek USA, #4583), sectioned to 10-μm, and counterstained with Hoechst 33258 dye. Some samples were also stained for WNV antigen as described above. Images were acquired using a Zeiss LSM 880 Confocal Laser Scanning Microscope 20x (NA 0.8) objective. Each data point was derived from measurements of 3 to 5 independent fields per mouse per brain.

Bacteria culture
At the time of necropsy, approximately 500 μL of blood was steriley collected from each mouse via cardiac puncture and transferred to sterile collection tubes containing EDTA (Becton Dickinson, #365974). Blood was diluted in sterile 1X DMEM (no antibiotics or FBS) and serial dilutions were made (undiluted, 1:10 and 1:100). Approximately 50 μL of blood and diluted samples from each mouse was plated on pre-warmed sheep blood agar plates (Fisher Scientific, # B21261) using L-shaped spreaders. Plates were incubated at 37°C overnight, and the number of colonies was enumerated on the following day.

BBB permeability assay
BBB integrity was evaluated by examining extravasation of dextrans of different sizes from the blood into the brain. Briefly, mice were anesthesized and administered by intravenous injection 100 μL of 40 mg/mL dextrans conjugated to FITC (250 kDa, Sigma-Aldrich, #FD2500) or tetramethylrhodamine (TRITC) (70 kDa, Thermo, #D1818). After 25 min, mice were administered terminal anesthesia with ketamine/xylazine. Subsequently, brains were harvested, fixed in 4% PFA overnight at 4°C, cryoprotected with 30% sucrose over 48 h, embedded in Tissue-Tek O.C.T. Compound (Sakura Finetek USA, #4583), frozen, and then sectioned to 30-μm depth by Cryostat (Leica, #CM1850). Sections were counterstained with Hoechst 33258 (1:10,000 in 1X PBS, Thermo Fisher #H3569), mounted in ProLong Glass Antifade Mountant (Invitrogen #P36980) and stored in the dark at 4° C until imaging. All images were acquired using a Zeiss LSM 880 Confocal Laser Scanning Microscope 20x (NA 0.8) objective Image processing and analysis was performed using ImageJ. The number of Iba1+ cells were counted per field. The area of Iba1 staining was quantified by converting images to binary using a threshold tool from at least 20 microglia/macrophage cells in each field and then dividing by the number of microglia/macrophage nuclei counted. Each data point was derived from measurements of at least 3 independent fields per mouse brain.

Anti-type I IFN ELISA
Assays were performed in 96-well ELISA plates (MaxiSorp; Thermo Fisher Scientific). The plates were coated with 2 μg/mL of recombinant human IFN-α2a (Milenyi Biotec, #130-093-874), IFN-β1 (Milenyi Biotec, #130-107-888) or IFN-ω (Sigma, #SRP3061) in ELISA coating buffer (Na2CO3 and NaHCO3, 0.05 M Carbonate-Bicarbonate, pH 9.6) overnight at 4°C. Plates were rinsed eight times with PBST (PBS with 0.05% Tween-20), blocked after incubation with 5% human serum albumin (Sigma, #A17653) in PBST, rinsed eight times, and then incubated with serum from WNV patients (1:25), positive serum controls (1:100, obtained from S. Holland, National Institutes of Health) and negative naive serum controls (1:25) for 2 h at room temperature. Plates were rinsed 8 times with PBST and then incubated with horseradish peroxidase (HRP)-conjugated Fc-specific goat anti-human IgG/IgA/IgM (1:10,000, Nordic Immunological Laboratories) in PBST, rinsed eight times, and then incubated with 3,3′,5,5′-Tetramethylbenzidine (Thermo #34029) substrate was added as 100 μL per well for 5 min and stopped with 2 N H2SO4 (100 μL/well), and the optical density (OD) at 450 nm wavelength was measured. An OD value above the average of all negative samples plus six times their standard deviation (Background Avg + 6x SD) was defined as a positive signal.

IFN neutralization assay
The neutralizing activity against IFN-α or IFN-ω was determined using a published reporter luciferase activity32. Briefly, HEK293T cells were transfected with a Firefly luciferase reporter plasmid under the control of the human ISRE promoter in the pGL4.45 backbone using X-tremeGene9 transfection reagent (Sigma-Aldrich, #635779001), with the plasmid constitutively expressing Renilla luciferase for normalization (pRL-SV40). One day later, transfected cells cultured in DMEM (Thermo Fisher Scientific, #11965-084) supplemented with 2% FBS and 10% asymptomatic control or neuroinvasive patient serum/plasma (after heat-inactivation at 56°C, for 20 min) were either left unstimulated or were stimulated with IFN-α2 (Milenyi Biotec, #130-108-984) or IFN-ω (Peprotech, #300-02 J) at 10 ng/mL for 16 h at 37°C. Cells were lysed, and luciferase levels were measured with the Dual-Luciferase® Reporter 1000 assay kit (Promega, #E1980), against a VICTOR Nivo Multimode Microplate Reader (PerkinElmer Life Sciences, USA). Firefly luciferase activity values were normalized against Renilla luciferase activity values. ISRE induction values were then normalized against the median induction values for non-neutralizing samples and expressed as percentages. Samples were considered neutralizing if the fold induction was below 15% of the median values for non-neutralizing controls.

IFN neutralization in human enteroid cultures
Wild-type or IFNAR1-KO human enteroids were pretreated with either 20 ng/mL of IFN-α2 for 8 h directly or IFN-ω in the presence of 10% (v/v) patient serum sample for 8 h. The treated wells were then inoculated 2×10^4 FFU of LCMV clone 13 (MOI of 0.1) for 2 h at 37°C in 5% CO2. The supernatants with virus inoculum then were harvested as input, and cells were washed twice with medium to remove unbound viruses. Inoculated wells were then supplemented with 100 μL/well of WRNE medium and cultured for 48 h at 37°C in 5% CO2. Samples were assessed for LCMV replication by RT-qPCR. In WNV infection studies,
wild-type human enteroids were pretreated with 100 pg/mL of IFN-α2 for 8 h with or without 10% (v/v) patient sera for 8 h. The treated wells were then inoculated 2 × 10^3 FFU of WNV (MOI of 0.1) for 2 h at 37 °C in 5% CO₂. The supernatants were harvested as a measure of input virus, and cells were washed twice with medium to remove unbound viruses. Wells were then supplemented with 100 µL/well of WRNE medium and cultured for 72 h at 37 °C in 5% CO₂. Samples were collected and assessed for WNV replication by RT-qPCR.

Statistical analysis
Experimental animals were randomized throughout the study, and scoring of immunofluorescence and histology images was performed in a blinded manner. Statistical analyses were performed with Prism 9.0. Mann-Whitney, one-way ANOVA, and two-way ANOVA tests were used to determine significance with Bonferroni correction for multiple comparisons. Details of statistical tests, number of animals, mean values, and comparison groups are included in the Figure Legends. In the initial trials, two GF mice that received anti-IFNAR1 antibodies via intraperitoneal injection were excluded from analysis after testing of sera and tissues failed to reveal detectable WNV RNA in tissues at 5 dpi, consistent with unsuccessful systemic delivery of anti-IFNAR1. All subsequent GF mice received anti-IFNAR1 antibodies via retroorbital injection and demonstrated markedly elevated levels of WNV RNA, as anticipated.

Reporting summary
Further information on research design is available in the Nature Portfolio Reporting Summary linked to this article.

Data availability
All data supporting the findings of this study are available within the main text and supplemental data. Source data for main and supplemental figures are provided with this paper. Source data are provided with this paper.

References
32. Bastard, P. et al. Autoantibodies neutralizing type I IFNs are present in ~4% of uninfected individuals over 70 years old and account for ~20% of COVID-19 deaths. Sci. Immunol. 6, eabd4340 (2021).
64. Doldan, P. et al. Type III and Not Type I Interferons Efficiently Prevent the Spread of Rotavirus in Human Intestinal Epithelial Cells. J. Virol. 96, e0070622 (2022).
Acknowledgements
We thank Michelle Elam-Noll posthumously for her assistance with mouse husbandry. We acknowledge the Washington University Gnotobiotic Core Facility for assistance with germ-free mouse experiments, and Dr. Wandy L. Beatty in the Washington University Molecular Microbiology Imaging Facility for assistance with confocal microscopy imaging. The studies were supported by NIH grants R01AI073755 and R01DK122790 (awarded to M.S.D.), and K23AI057341 and R01AI091816 (awarded to K.O.M.). F.R.Z. was supported by a Rheumatology Research Foundation Scientist Development Award. The Laboratory of Human Genetics of Infectious Diseases is supported by the Howard Hughes Medical Institute, the Rockefeller University, the St. Giles Foundation, the National Institutes of Health (NIH) (R01AI63029), the National Center for Advancing Translational Sciences (NCATS), NIH Clinical and Translational Science Award (CTSA) program (UL1TR001866), the Fisher Center for Alzheimer Research Foundation, the Meyer Foundation, the JPB Foundation, the program “Investissement d’Avenir” launched by the French Government and implemented by the Agence Nationale de la Recherche (ANR) (ANR-10-IAHU-01), the Integrative Biology of Emerging Infectious Diseases Laboratory of Excellence (ANR-10-LABX-62-IBED), the French Foundation for Medical Research (FRM) (EQU201903007798), ANR A2ID (ANR-22-CE15-0046), the European Union’s Horizon 2020 research and innovation programme under grant agreement No 824110 (EASI-genomics), the HORIZON-CLRT-2021-DISEASE-04 program under grant agreement 1057100 (UNDINE), the ANR-RHU COVIFERON Program (ANR-21-RHUS-08), the Square Foundation, Grandir - Fondos de solidarité pour l’enfance, the Fondation du Souffle, the SCOR Corporate Foundation for Science, The French Ministry of Higher Education, Research, and Innovation (MESRI-COVID-19), Institut National de la Santé et de la Recherche Médicale (INSERM), REACTing-INSERM and the University of Paris.

Author contributions
S-C.L. performed organoid experiments, mouse infection, tissue harvesting, RT-qPCR, immunofluorescence staining, confocal imaging and auto-Ab ELISA. F.R.Z. performed mouse treatments and infection, gut and BBB permeability assays, tissue harvesting, RT-qPCR, immunofluorescence imaging, and data analysis. H.J. performed mouse infections, tissue harvesting, BBB permeability assays, and confocal microscopy imaging. A.G. performed Luciferase assays. S.R. performed GF mouse experiments. K.O.M. and J-L.C. proved human serum samples and helped to design auto-Ab experiments. S-C.L., F.R.Z., and M.S.D. designed studies and wrote the initial draft, with all other authors providing editorial comments.

Competing interests
M.S.D. is a consultant or advisor for Inbios, Vir Biotechnology, Senda Biosciences, Ocugen, Topsin Therapeutics, Moderna, and Immunome. The Diamond laboratory has received unrelated funding support in sponsored research agreements from Vir Biotechnology, Emergent Biosolutions, and Moderna. J.-L.C. is an inventor on patent application PCT/US2021/042741 submitted by Rockefeller University that covers diagnosis of susceptibility to, and treatment of, viral disease and viral vaccines. The remaining authors declare no competing interests.

Additional information

Supplementary information The online version contains supplementary material available at https://doi.org/10.1038/s41467-023-41600-3.

Correspondence and requests for materials should be addressed to Michael S. Diamond.

Peer review information Nature Communications thanks the anonymous reviewers for their contribution to the peer review of this work.

Reprints and permissions information is available at http://www.nature.com/reprints

Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.

© The Author(s) 2023